Protease inhibitors of the coagulation cascade isolated from dysidea sponges
AssigneePharmacia Corporation
InventorsGilles H. Goetz, George G. Harrigan, John J. Likos, Thomas P. Kasten
Life of this patent
Estimating the term…
Abstract
The present invention is directed toward a composition comprising a compound isolated from Dysidea species sponges that is capable of inhibiting serine proteases of the coagulation cascade. In particular, this composition inhibits the TF/VIIa complex of the coagulation cascade. The invention is also directed toward methods employing this composition as a part of anticoagulant therapy.
Claims24
A compound having the structure:
- 3
- or a pharmaceutically acceptable salt, prodrug, tautomer or isomer thereof.
A method for treating or preventing a thrombolytic condition in a subject, the method comprising administering to the subject a compound having the structure:
- 4
- or a pharmaceutically acceptable salt, tautomer, prodrug or isomer thereof.
A method for substantially inhibiting thrombus formation in a subject, the method comprising administering to the subject a compound having the structure:
- 5
- or a pharmaceutically acceptable salt, tautomer, prodrug or isomer thereof.
A method for substantially inhibiting an enzyme involved in the coagulation cascade, the method comprising administering to a subject a compound having the structure:
- 6
- or a pharmaceutically acceptable salt, tautomer, prodrug, or isomer thereof.
An extract of a Dysidea sponge comprising a compound having the structure:
- 7
- or a pharmaceutically acceptable salt, prodrug, tautomer or isomer thereof.
Dependencies are inferred from the claim text.